ジオスシン (Synonyms: Dioscin; Collettiside III; CCRIS 4123)

Name: Dioscin
Brand: MedChemExpress
SKU: HY-N0124
Rating: 5.0 (11 reviews)

製品番号: HY-N0124 純度: 99.95%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Dioscin (CCRIS 4123; Collettiside III) is a natural plant-derived steroidal saponin that has good anti-cancer activity against a variety of cancer cells. Dioscin causes DNA damage and induces apoptosis in HeLa and SiHa cells. Dioscin regulates ROS-mediated DNA damage and mitochondrial signaling pathways, exerting anticancer activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 19057-60-4

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 69	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 69	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$36	在庫あり	Estimated Time of Arrival: December 31
10 mg	$58	在庫あり	Estimated Time of Arrival: December 31
25 mg	$99	在庫あり	Estimated Time of Arrival: December 31
50 mg	$138	在庫あり	Estimated Time of Arrival: December 31
100 mg	$190	在庫あり	Estimated Time of Arrival: December 31
500 mg	$380	在庫あり	Estimated Time of Arrival: December 31
1 g		お問い合わせ
5 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

Other Forms of Dioscin:

Dioscin (Standard) 在庫あり

顧客検証

RT-PCR

Histological Imaging/Staining

Flow Cytometry

: Dioscin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Nov 11.; Dioscin (200 nM, 24 h) alleviates gout by inhibiting hypoxia-inducible factor 1-alpha (HIF-1α) in CD4+ T cells. Quantitative PCR analysis revealing significantly elevated mRNA levels of HIF-1α after DIO treatment (n = 3).

: Dioscin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Nov 11.; Dioscin (200 nM, 24 h) alleviates gout by inhibiting hypoxia-inducible factor 1-alpha (HIF-1α) in CD4+ T cells. Western blot analysis revealing significantly elevated protein levels of HIF-1α after DIO treatment (n = 3).

: Dioscin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Nov 11.; Representative images and hematoxylin and eosin (H&E) analysis of footpads after IOX4 and Dioscin (20 mg/kg, intraperitoneal injection weekly over a six-week period) treatment (n = 3).

: Dioscin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Nov 11.; Pull-down analysis between Dioscin (200 nM, 24 h) and HIF-1α in primary CD4+ T cells (n = 3).

: Dioscin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Nov 11.; Dioscin (20 mg/kg, intraperitoneal injection weekly over a six-week period) reshapes CD4+ T cell differentiation via hypoxia-inducible factor 1-alpha (HIF-1α). T helper 17 (Th17) cell proportions in the blood, intestine, and spleen of DIO-treated urate oxidase (Uox)-knockout (KO) mice (n = 8).

: Dioscin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Nov 11.; Dioscin (20 mg/kg, intraperitoneal injection weekly over a six-week period) reshapes CD4+ T cell differentiation via hypoxia-inducible factor 1-alpha (HIF-1α). Multiplex immunofluorescence staining of Th17 cells in the footpad of DIO-treated Uox-KO mice (n = 3): representative images and quantitative analysis of Th17 cell numbers.

: Dioscin purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Apr:117:109839. [Abstract]; Dioscin-Medium group (5 mg/kg; p.o.; every-two days for 12 weeks) profoundly inhibits the phosphorylation of NF-ĸB in mice (Fig H and I). Dioscin-Low (Dio-L, 2.5 mg/kg), Dioscin-Medium (Dio-M, 5 mg/kg) and Dioscin-High (Dio-H, 10 mg/Kg).

: Dioscin purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2017 Oct;16(4):4922-4926. [Abstract]; Dioscin concentrations of 0.5, 1, 5, 10 and 25 µg/mL promotes the expression of ALP and inhibits the expression of LC3B in MC3T3-E1 cells, in a concentration-dependent manner.

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.581 μM Compound: Dioscin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 21482468]
A2780	IC₅₀	0.87 μM Compound: Dioscin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 22429911]
A2780	IC₅₀	4.46 μM Compound: Dioscin	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	0.454 μM Compound: Dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21482468]
A549	IC₅₀	0.7 μM Compound: Dioscin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22429911]
A549	IC₅₀	4.2 μM Compound: dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 16905317]
BGC-823	IC₅₀	0.268 μM Compound: Dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21482468]
BGC-823	IC₅₀	1.08 μM Compound: Dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 22429911]
BGC-823	IC₅₀	2 μM Compound: dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 16905317]
BXPC-3	GI₅₀	1.3 μg/mL Compound: 4, dioscin	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
BXPC-3	IC₅₀	0.7 μM Compound: Dioscin	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19362474]
Bel-7402	IC₅₀	0.23 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19362474]
Bel-7402	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 22429911]
Bel-7402	IC₅₀	0.93 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 21482468]
Capan-2	IC₅₀	0.05 μM Compound: Dioscin	Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay	[PMID: 19362474]
Col2	IC₅₀	2.8 μM Compound: 2	Cytotoxicity against human Col2 cells after 72 hrs by SRB assay Cytotoxicity against human Col2 cells after 72 hrs by SRB assay	[PMID: 12088425]
DU-145	GI₅₀	> 10 μg/mL Compound: 4, dioscin	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
HCT-8	IC₅₀	0.34 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 22429911]
HCT-8	IC₅₀	0.351 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 21482468]
HCT-8	IC₅₀	0.56 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19362474]
HGC-27	IC₅₀	5.9 μM Compound: dioscin	Cytotoxicity against human HGC27 cells by MTT assay Cytotoxicity against human HGC27 cells by MTT assay	[PMID: 16905317]
HL-60	IC₅₀	2 μM Compound: 6	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 12828464]
HL-60	IC₅₀	3.8 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22405922]
HeLa	IC₅₀	0.5 μM Compound: Dioscin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22429911]
K562	IC₅₀	4.7 μM Compound: 1	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23621869]
K562/Adr	IC₅₀	3.3 μM Compound: 1	Cytotoxicity against human K562/ADR cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23621869]
KB	ED₅₀	21 μM Compound: 8	Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
KB	IC₅₀	0.53 μM Compound: Dioscin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 22429911]
KB	IC₅₀	20.7 μM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 12088425]
KB-V1	IC₅₀	> 23 μM Compound: 2	Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay	[PMID: 12088425]
KETR3	IC₅₀	0.447 μM Compound: Dioscin	Cytotoxicity against human Ketr3 cells by MTT assay Cytotoxicity against human Ketr3 cells by MTT assay	[PMID: 21482468]
KM-20L2	GI₅₀	1.3 μg/mL Compound: 4, dioscin	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
LNCaP	ED₅₀	1.7 μM Compound: 8	Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
LNCaP	IC₅₀	1.7 μM Compound: 2	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 12088425]
Lu1	ED₅₀	1.2 μM Compound: 8	Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
Lu1	IC₅₀	1.2 μM Compound: 2	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 12088425]
MCF7	GI₅₀	0.68 μg/mL Compound: 4, dioscin	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	0.879 μM Compound: Dioscin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21482468]
MCF7	IC₅₀	1.03 μM Compound: Dioscin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19362474]
MCF7	IC₅₀	22.4 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 12088425]
NCI-H460	GI₅₀	1.8 μg/mL Compound: 4, dioscin	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NCI-H460	IC₅₀	4.56 μM Compound: 12	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
P388	ED₅₀	> 10 μg/mL Compound: 4, dioscin	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
P388	IC₅₀	21.9 μM Compound: 2	Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay	[PMID: 12088425]
PANC-1	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 19362474]
SF-268	GI₅₀	1.2 μg/mL Compound: 4, dioscin	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SK-MEL-2	IC₅₀	1.8 μM Compound: 2	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay	[PMID: 12088425]
SW1990	IC₅₀	0.5 μM Compound: Dioscin	Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 19362474]
SW626	IC₅₀	3.1 μM Compound: 2	Cytotoxicity against human SW626 cells after 72 hrs by SRB assay Cytotoxicity against human SW626 cells after 72 hrs by SRB assay	[PMID: 12088425]

体外実験

Dioscin (1.25-5 μg/mL; 6-24 h) increases intracellular calcium levels and induces apoptosis in HeLa and SiHa cells^[4].
Dioscin (1.25-5 μg/mL; 6-24 h) Dioscin up-regulates the protein levels of Bak, Bax, Bid, p53, caspase-3, caspase-9, and down-regulates the proteins of Bcl-2 and Bcl-xl level^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Dioscin (75-300 mg/kg, 10 mL/kg; oral gavage; 90 days) has no subchronic toxicity in female rats and mild subchronic toxicity in male rats. Dioscin caused mild gastrointestinal dilatation in male rats and demonstrated hemolytic anemia on hematological evaluation^[5].
Dioscin can reduce liver ischemia-reperfusion injury in rats by inhibiting oxidative-nitrative stress, inflammation and apoptosis^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

869.04

分子式

C₄₅H₇₂O₁₆

CAS 番号

19057-60-4

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1[C@@H](O)[C@H](C)O[C@@]([H])(O[C@H]2[C@H](O)[C@@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@](O[C@@H]4CC5=CC[C@]([C@]([H])(C[C@@]6([H])[C@]7([H])[C@H](C)[C@]8(OC[C@H](C)CC8)O6)[C@]7(C)CC9)([H])[C@@]9([H])[C@@]5(C)CC4)([H])O[C@@H]2CO)[C@@H]1O

Structure Classification

Steroids

Initial Source

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (115.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1507 mL	5.7535 mL	11.5070 mL
5 mM	0.2301 mL	1.1507 mL	2.3014 mL
10 mM	0.1151 mL	0.5753 mL	1.1507 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (2.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.25 mg/mL (2.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.25 mg/mL (2.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (5.75 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.95%

Select Batch:

データシート (280 KB) SDS (393 KB)

COA (256 KB) HNMR (340 KB) RP-HPLC (213 KB) MS (69 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Chen J, et al. Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family. J Huazhong Univ Sci Technolog Med Sci. 2014 Feb;34(1):125-30. [Content Brief]

[2]. Qu X, et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem Biophys Res Commun. 2014 Jan 10;443(2):658-65. [Content Brief]

[3]. Qin J, et al. Dioscin prevents the mitochondrial apoptosis and attenuates oxidative stress in cardiac H9c2 cells. Drug Res (Stuttg). 2014 Jan;64(1):47-52. [Content Brief]

[4]. Zhao X, et al. Dioscin Induces Apoptosis in Human Cervical Carcinoma HeLa and SiHa Cells through ROS-Mediated DNA Damage and the Mitochondrial Signaling Pathway. Molecules. 2016 Jun 4;21(6):730. [Content Brief]

[5]. Xu T, et al. A 90-day subchronic toxicological assessment of dioscin, a natural steroid saponin, in Sprague-Dawley rats. Food Chem Toxicol. 2012 May;50(5):1279-87. [Content Brief]

[6]. Tao X, et al. Dioscin attenuates hepatic ischemia-reperfusion injury in rats through inhibition of oxidative-nitrative stress, inflammation and apoptosis. Transplantation. 2014 Sep 27;98(6):604-11. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1507 mL	5.7535 mL	11.5070 mL	28.7674 mL
	5 mM	0.2301 mL	1.1507 mL	2.3014 mL	5.7535 mL
	10 mM	0.1151 mL	0.5753 mL	1.1507 mL	2.8767 mL
	15 mM	0.0767 mL	0.3836 mL	0.7671 mL	1.9178 mL
	20 mM	0.0575 mL	0.2877 mL	0.5753 mL	1.4384 mL
	25 mM	0.0460 mL	0.2301 mL	0.4603 mL	1.1507 mL
	30 mM	0.0384 mL	0.1918 mL	0.3836 mL	0.9589 mL
	40 mM	0.0288 mL	0.1438 mL	0.2877 mL	0.7192 mL
	50 mM	0.0230 mL	0.1151 mL	0.2301 mL	0.5753 mL
	60 mM	0.0192 mL	0.0959 mL	0.1918 mL	0.4795 mL
	80 mM	0.0144 mL	0.0719 mL	0.1438 mL	0.3596 mL
	100 mM	0.0115 mL	0.0575 mL	0.1151 mL	0.2877 mL

Dioscin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

ジオスシン (Synonyms: Dioscin; Collettiside III; CCRIS 4123)

カスタマーレビュー

Other Forms of Dioscin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Dioscin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

ジオスシン (Synonyms: Dioscin; Collettiside III; CCRIS 4123)

カスタマーレビュー

Other Forms of Dioscin:

ジオスシン 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

ジオスシン 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Dioscin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

ジオスシン関連抗体

ジオスシン関連抗体